United Therapeutics (UTHR) Non-Current Assets (2009 - 2026)

United Therapeutics has disclosed Non-Current Assets across 18 years of filings, most recently posting $3.8 billion for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $3.8 billion, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.0 billion (up 18.03% YoY), and the FY2025 annual result was $4.2 billion, up 19.7% from the prior year.
• Non-Current Assets came in at $3.8 billion for Q1 2026 at United Therapeutics, down from $4.2 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.2 billion in Q4 2025 to a low of $883.7 million in Q4 2022.
• The 5-year median for Non-Current Assets is $3.2 billion (2024), against an average of $3.1 billion.
• Peak annual rise in Non-Current Assets reached 226.24% in 2024, while the deepest fall reached 12.4% in 2024.
• United Therapeutics' Non-Current Assets stood at $883.7 million in 2022, then gained by 21.06% to $1.1 billion in 2023, then jumped by 226.24% to $3.5 billion in 2024, then increased by 19.7% to $4.2 billion in 2025, then declined by 8.03% to $3.8 billion in 2026.
• The last three Non-Current Assets figures came in at $3.8 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.9 billion (Q3 2025), per Business Quant data.